Bristol-Myers Squibb has swooped in with $60 million upfront to gain an option on Bavarian Nordic's Phase III therapeutic prostate cancer vaccine Prostvac, ready to shell out an additional $915 million-plus in milestones if it takes the next step to license and ultimately commercialize the therapy.
Rare disease magnate Alexion is aligning itself with biotech Blueprint Medicines, borrowing the company's development technology to spotlight new treatments for genetic disorders.
Gilead Sciences has been busy in India and Japan signing licensing agreements for at least four of its drugs.
Japan's Takeda Pharmaceutical has looked at Indian companies in the vaccine space as it moves to tighten focus on that aspect of its business ahead of a Phase III trial for a dengue candidate and more broadly emerging markets as seen by a recent M&A deal in Turkey.
Cleveland-based Athersys is pocketing a $10 million upfront payment from Chugai in exchange for licensing rights to the biotech's stem cell treatment for repairing stroke damage. The Japanese pharma company, which has close relations with Roche, also stands to earn up to $45 million in development and regulatory milestones with another $150 million in sales milestones.
Today, Kite expanded its research and development deal--or CRADA--with some key researchers at the National Cancer Institute to cover additional programs and targeting tools needed to beef up its pipeline during a critical stage of development for this hotly competitive niche in the cancer arena.
China's Eddingpharm has been granted rights by Amarin to sell hypertriglyceridemia drug Vascepa icosapent ethyl in Greater China.
Akili Interactive Labs has partnered with the nonprofit Autism Speaks to conduct a clinical trial of its cognitive assessment and personalized treatment video game.
Chugai and U.S.-based Athersys Inc. agreed to partner in a license agreement on the development of a stem cell therapy for ischemic stroke that includes clinical trial work in Japan.
AstraZeneca is out to get some more shots on goal in immunology, pairing up with a nascent biotech in hopes of developing oral medicines for psoriasis, arthritis and other diseases.